Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.50 -0.3%	$12.74	$8.04 ▼ $25.88	$366.12M	2.27	416,496 shs	277,323 shs
ATXS Astria Therapeutics	$5.97 -4.3%	$5.30	$3.56 ▼ $12.92	$336.89M	0.41	377,514 shs	198,157 shs
HUMA Humacyte	$2.33 -3.7%	$2.33	$1.15 ▼ $9.79	$361.43M	1.89	3.77 million shs	1.55 million shs
OKYO OKYO Pharma	$2.99 +3.1%	$2.21	$0.81 ▼ $3.11	$101.18M	-0.09	175,056 shs	306,152 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+5.37%	-6.49%	+10.26%	+28.58%	-44.23%
ATXS Astria Therapeutics	-1.42%	-6.45%	+9.47%	+54.46%	-44.92%
HUMA Humacyte	+1.26%	-3.59%	+3.86%	+44.05%	-70.38%
OKYO OKYO Pharma	-2.03%	+1.40%	+31.22%	+137.70%	+81.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	1.9703 of 5 stars	3.6	0.0	1.9	2.5	0.6
ATXS Astria Therapeutics	1.6297 of 5 stars	3.6	1.0	1.6	1.7	0.0
HUMA Humacyte	1.5779 of 5 stars	3.5	1.0	1.4	0.8	0.6
OKYO OKYO Pharma	3.1275 of 5 stars	3.5	5.0	3.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	300.00% Upside
ATXS Astria Therapeutics	3.25	Buy	$30.00	402.51% Upside
HUMA Humacyte	3.00	Buy	$11.71	402.76% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	134.11% Upside

Current Analyst Ratings Breakdown

Latest OKYO, ARCT, HUMA, and ATXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/14/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$47.00 ➝ $47.00
5/14/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/14/2025	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $14.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.40	N/A	N/A	$8.90 per share	1.52
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.97 per share	N/A
HUMA Humacyte	$1.57M	230.21	N/A	N/A	($0.41) per share	-5.68
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.20) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
ATXS Astria Therapeutics	-$94.26M	-$1.87	N/A	N/A	N/A	N/A	-47.18%	-31.26%	8/11/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	8/12/2025 (Estimated)
OKYO OKYO Pharma	-$16.83M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)

Latest OKYO, ARCT, HUMA, and ATXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	HUMA Humacyte	-$0.15	N/A	N/A	N/A	$0.94 million	N/A
8/11/2025	Q2 2025	ATXS Astria Therapeutics	-$0.61	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
ATXS Astria Therapeutics	N/A	17.39	17.39
HUMA Humacyte	0.36	3.68	3.28
OKYO OKYO Pharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
ATXS Astria Therapeutics	98.98%
HUMA Humacyte	44.71%
OKYO OKYO Pharma	2.97%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
ATXS Astria Therapeutics	4.50%
HUMA Humacyte	5.10%
OKYO OKYO Pharma	40.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
ATXS Astria Therapeutics	30	56.43 million	53.89 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
OKYO OKYO Pharma	7	33.84 million	20.15 million	Not Optionable

OKYO, ARCT, HUMA, and ATXS Headlines

Recent News About These Companies

OKYO Slides Despite Fresh R&D Funding

July 17 at 1:04 PM | baystreet.ca

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

July 17 at 1:04 PM | finance.yahoo.com

OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development

July 17 at 9:34 AM | tipranks.com

OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy

July 17 at 9:31 AM | proactiveinvestors.com

OKYO reports top-line data from neuropathic corneal pain therapy trial

July 17 at 8:02 AM | finance.yahoo.com

Okyo sets sights on first approval in neuropathic eye pain after phase 2 win

July 16 at 5:00 PM | fiercebiotech.comF

OKYO Pharma shares surge following promising Phase 2 data for eye pain treatment

July 16 at 5:00 PM | msn.com

Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation

July 16 at 1:00 PM | tipranks.com

OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain

July 16 at 10:22 AM | tipranks.com

OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain

July 16 at 9:42 AM | proactiveinvestors.com

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

July 16 at 9:21 AM | globenewswire.com

OKYO Pharma (NASDAQ:OKYO) Trading Up 1% - Here's Why

July 10, 2025 | marketbeat.com

OKYO Pharma (NASDAQ:OKYO) Shares Down 13.7% - Should You Sell?

June 18, 2025 | marketbeat.com

OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders

June 14, 2025 | uk.finance.yahoo.com

OKYO Pharma to Present at the Bio International Convention

June 11, 2025 | manilatimes.netM

OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts

June 11, 2025 | proactiveinvestors.com

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | OKYO Stock News

June 11, 2025 | gurufocus.com

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

June 11, 2025 | accessnewswire.comA

OKYO Pharma CEO to Present Urcosimod Development for Neuropathic Corneal Pain at Bio International Convention 2025

June 11, 2025 | quiverquant.comQ

Tokyo stocks edge down amid caution over U.S.-China trade tensions

June 3, 2025 | msn.com

OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit

May 19, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO, ARCT, HUMA, and ATXS Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.50 -0.04 (-0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$13.58 +0.07 (+0.56%)

As of 04:37 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Astria Therapeutics NASDAQ:ATXS

$5.97 -0.27 (-4.33%)

Closing price 04:00 PM Eastern

Extended Trading

$5.96 -0.01 (-0.17%)

As of 04:04 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Humacyte NASDAQ:HUMA

$2.33 -0.09 (-3.72%)

Closing price 04:00 PM Eastern

Extended Trading

$2.37 +0.04 (+1.72%)

As of 04:33 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

OKYO Pharma NASDAQ:OKYO

$2.99 +0.09 (+3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$2.99 0.00 (0.00%)

As of 04:36 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time